Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases. The ACRS news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates, and investor events drawn from press releases and regulatory disclosures.
Recent Aclaris news has focused on its immunology pipeline, including ATI-2138, a potent and selective oral ITK/JAK3 inhibitor, and its antibody franchise targeting TSLP and IL-4/IL-13 pathways. The company has reported positive Phase 2a results for ATI-2138 in moderate-to-severe atopic dermatitis, initiation and progress of a Phase 2 trial of its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis, and Phase 1a and Phase 1b development of its bispecific anti-TSLP/IL-4Rα antibody ATI-052, including a Phase 1b proof-of-concept trial in atopic dermatitis.
Investors and followers of ACRS can use this news feed to track key milestones such as interim and top line clinical results, updates on additional indications for ATI-2138, and timelines for proof-of-concept and later-stage trials. The page also captures corporate developments, including quarterly and year-to-date financial results, cash runway commentary, index inclusions such as the Nasdaq Biotechnology Index, and participation in healthcare and biotechnology conferences and R&D Day events.
By reviewing the ACRS news page regularly, readers can follow how Aclaris communicates progress across its oral kinase inhibitor and biologics franchises, how it describes the evolution of its multi-stage portfolio, and how financial and strategic updates align with its stated focus on patients with immuno-inflammatory diseases who lack satisfactory treatment options.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced promising topline results from a 12-week, Phase 2a trial of ATI-450, an investigational oral MK2 inhibitor, for rheumatoid arthritis. The study showed durable clinical activity, with a significant 2.0 reduction in DAS28-CRP scores and 40% of treatment subjects achieving low disease activity by week 12. ATI-450 was generally well tolerated, with no serious adverse events reported. The company plans to advance ATI-450 to Phase 2b trials and publish full data analysis in a scientific journal.
Aclaris Therapeutics (ACRS) announced the establishment of a new Scientific Advisory Board comprising leading experts in immuno-inflammatory diseases. The board includes Drs. Stanley Cohen, Marco Colonna, James Krueger, and Michael Weinblatt, who bring extensive experience in rheumatology and immunology. Additionally, Aclaris expects preliminary topline data from the ATI-450-RA-201 Phase 2a trial for rheumatoid arthritis in January 2021. This development aims to enhance Aclaris’ R&D efforts in addressing unmet medical needs in immuno-inflammatory conditions.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 2, 2020, at 7:30 a.m. ET. Management will also be available for one-on-one virtual meetings on December 1 and 2. Investors can access a live audio webcast of the event through the company's website, with an archived version available for 30 days. Aclaris is focused on developing novel drug candidates for immuno-inflammatory diseases, supported by a robust R&D platform.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its Q3 2020 financial results and progress updates on clinical trials. The company initiated a Phase 2a trial of ATI-1777 for atopic dermatitis and dosed the first subject. Additionally, a Phase 2a trial for ATI-450 in cryopyrin-associated periodic syndrome commenced. Financial highlights included a net loss of $10.7 million for Q3 2020 compared to $55.3 million in Q3 2019, and total revenue increased to $1.4 million, up from $1.0 million. Aclaris reported cash reserves of $55.2 million as of September 30, 2020, sufficient for operations through Q1 2022.
Aclaris Therapeutics (NASDAQ: ACRS) announced the dosing of the first patient in its Phase 2a clinical trial for ATI-1777, a topical JAK 1/3 inhibitor targeting moderate to severe atopic dermatitis (AD). The trial, enrolling approximately 42 subjects across multiple sites in the U.S., aims to assess the drug's efficacy, safety, and pharmacokinetics over 28 days. The primary endpoint is the change in the Eczema Area and Severity Index (EASI) score at week 4. The trial marks a significant step in Aclaris’ development of novel treatments for immuno-inflammatory diseases.
On September 1, 2020, Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in two upcoming virtual investor conferences. The first is the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 15, 2020, at 12:30 p.m. ET, featuring a presentation by President and CEO Dr. Neal Walker. The second event is the Cantor Virtual Global Healthcare Conference on September 17, 2020, at 10:40 a.m. ET, where Dr. Walker will take part in a fireside chat. Live webcasts will be available on the company’s website for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) received FDA approval for an investigational new drug application to study ATI-450 in hospitalized COVID-19 patients. This Phase 2a trial, led by the University of Kansas Medical Center, aims to evaluate the efficacy of ATI-450 in mitigating cytokine release syndrome (CRS) in 36 patients. The study's primary endpoint is the proportion of patients free from respiratory failure by day 14. ATI-450 has shown potential in reducing multiple inflammatory cytokines, indicating its promise in addressing severe COVID-19 symptoms.
WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics (NASDAQ: ACRS) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 1:00 p.m. ET. The presentation will provide a company overview, which can be accessed via a live audio webcast on Aclaris’ website, with an archived version available for 30 days. Aclaris is dedicated to treating immuno-inflammatory diseases, featuring a diverse portfolio that includes a late-stage drug candidate supported by a strong R&D initiative.
Aclaris Therapeutics reported financial results for Q1 2020, highlighting a net loss of $15.6 million, down from $37.6 million in Q1 2019.
Cash and equivalents rose to $79 million, with $11 million borrowed from Silicon Valley Bank to extend its cash runway into Q1 2022. The company resumed enrollment in its Phase 2a trial for ATI-450 amidst COVID-19 disruptions. R&D expenses decreased to $9.4 million, a drop of $10.2 million from the previous year, alongside a $1.8 million non-cash charge impacting financial results. Aclaris continues to seek partners for various product developments.